Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 36% of resolved cases
Pierre Paul Eleniste serves in Art Unit 1622 of Tech Center 1600 and has managed 93 resolved cases. The examiner has an allowance rate of 35.5 percent. This lower rate indicates a challenging prosecution environment where applicants must be prepared for rigorous scrutiny of their claims and a higher likelihood of initial rejections. The 93 resolved cases provide a clear picture of the examination hurdles in this unit.
The median time to allowance is 1317 days, reflecting a long-term engagement for those seeking a patent. However, the data highlights the effectiveness of interviews, which provide an interview lift of 31.2 percent. This substantial lift suggests that personal engagement with the examiner is an effective way to overcome rejections and improve the odds of a grant. Given the 35.5 percent allowance rate, leveraging the 31.2 percent lift is a critical tactical consideration for any practitioner appearing before this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18549693 | USE OF MEVIDALEN AND OTHER D1 POSITIVE ALLOSTERIC MODULATORS FOR SLOWING OF PARKINSON'S DISEASE PROGRESSION | Final Rejection | Eli Lilly and Company |
| 18518727 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF PROTAC, INCLUDING IU1-SERIES UBIQUITIN-SPECIFIC PROTEASE 14 INHIBITOR AS ACTIVE INGREDIENT | Non-Final OA | DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18852884 | THERAPEUTIC COMBINATION OF KRAS G12C INHIBITOR AND TEAD INHIBITOR | Non-Final OA | SANOFI |
| 18713747 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | Non-Final OA | Pfizer Inc. |
| 14443862 | SENSORILY ATTRACTIVE HYDRODISPERSION COMPRISING WAXES | Final Rejection | BEIERSDORF AG |
| 17421498 | COMPOUNDS AND TREATMENTS THAT ENHANCE ENTERIC NERVOUS SYSTEM FUNCTION | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18564008 | FRAGRANCE COMPOSITION | Non-Final OA | Kao Corporation |
| 18556241 | SMALL-MOLECULE INHIBITORS FOR BETA-CATENIN/BCELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17596832 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Final Rejection | Ascendis Pharma A/S |
| 18206506 | BIOLOGICAL ACTIVITIES OF 5-(2-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-6-METHOXYQUINOLIN-7-YLOXY)ETHYL)-5-AZASPIRO[2.4]-HEPTAN-7-OL CRYSTALLINE, PHOSPHORIC ACID SALT AND ITS ENANTIOMERS | Final Rejection | Advenchen Pharmaceuticals, LLC |
| 17276325 | MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT | Final Rejection | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (F.S. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy